FL-BOW-GROUP
29.7.2021 15:17:11 CEST | Business Wire | Press release
BOW Group today announced that it has successfully completed the acquisition of Musart.com , a fast-growing online destination to buy original artworks and licensed products. This transaction will allow BOW Group to seize new opportunities in the booming digital art market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005637/en/
“BOW Group and Musart share the same passion for good yet accessible design that brings emotions to consumers at every moment of the day,” said Boris Brault, BOW Group Founder and CEO. “Together, with Musart’s unique product curation and established relationships with leading institutions, we can conquer the thriving online art market thanks to our global ecommerce, logistics and development capabilities. With Musart in our portfolio, we are expanding our offering and enhancing the growth potential of our business beyond IoT and lifestyle objects. Today, the art world is fundamentally changing, disrupted with new players and media; we want to participate in that shift by helping consumers get access to art pieces and accessories, under different forms, at every price points.”
Since its inception in 2014, Musart has sold thousands of pieces of collectibles. Founded by French Art-Lover and Entrepreneur Vincent Gregoire, Musart’s mission is to make art accessible, giving anyone the opportunity to «own a piece of museum».
Partnerships with world-class museums, foundations and cultural organizations allow Musart to bring not only exclusive and authentic items, but also, to honor iconic artists such as Basquiat, Cattelan, Da Vinci, Dali, Haring, Hokusai, Kahlo, Klimt, Kusama, Magritte, Michelangelo, Miró, Modigliani, Mondrian, Picasso, Pollock, Van Gogh, Warhol. Licensed items, numbered and signed pieces include the world famous Kaws, Medicom Toy Be@rbricks and Kidrobot, as well as new promising talents. The selection spans multiple product categories: sculptures, home decor and office accessories, stationary, books, clothing, etc... with prices ranging from $20 to $20,000.
Customers receive not only an art piece but also a short biography of the corresponding artist for each purchase, proving Musart’s commitment to democratizing art and its educative vocation. Headquartered in Miami, Musart has first experienced a retail journey and embarked into a successful digital experience with its own website and 5-stars Central Seller page on Amazon, gathering today more than 1000 references and a highly active community of collectors.
By joining BOW Group, Musart will benefit from the group’s 360° platform, including a mature D2C digital ecosystem, multiple warehouse locations to serve consumers around the globe and its R&D center BOW Industries to handle its licensed and private label activities. One of the first objectives is to expand Musart’s sales activity outside the US, especially in Europe. While Musart will undoubtedly diversify BOW Group’s offering from a B2C standpoint, it will also meet the demand of B2B and Corporate customers with a whole new range of exciting gift objects.
Musart Founder Vincent Gregoire said: “I’m thrilled to join BOW Group with whom we share the same entrepreneurial mindset and consumer-driven approach. This integration marks a new chapter for Musart, one that will definitely help us reach our full potential at a global scale and embrace the new disruptive changes of our industry, such as NFTs. Leveraging BOW’s existing digital resources, ecommerce and supply chain infrastructure will take our business to another level, bringing innovative online experiences such as AR technology while continuing to make art accessible to anyone.”
Follow Musart
Instagram: https://www.instagram.com/musartboutique/
Facebook: https://www.facebook.com/musartboutique/
About BOW Group
BOW Group is a global player and multi-skilled platform operating worldwide with two consumer brands: Lexon , the design object editor, and MyKronoz , the IoT specialist - both powered by its own R&D and manufacturing center, BOW Industries. In addition, BOW Group owns the luxury concept-store chain Legacy .
Every year, BOW Group sells about 2 million pieces of products in 90 countries and across 9000 points of sales, thanks to its international recognition and network of leading designers celebrated with more than 200 Awards received, including 7 Red Dot Design Awards won by its two brands in 2021.
BOW Group has now more than 100 talents spread across four office locations: Paris, Geneva, Miami and Shenzhen.
Since July 2015, BOW has opened up its capital to NextStage AM , then, in 2017 to PM Equity Partner - the corporate venture fund of Philip Morris International .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005637/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
